Shield Therapeutics Plc (STX.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in thousands)
| 12-2015 | 12-2014 | |
| Cash Flows From Operating Activities | ||
| Accounts receivable | -2,261 | 34 |
| Other Working Capital | 1,933 | -294 |
| Other Operating Activity | -5,870 | -4,940 |
| Operating Cash Flow | $-6,197 | $-5,200 |
| Cash Flows From Investing Activities | ||
| PPE Investments | -13 | -19 |
| Purchase Sale Intangibles | -182 | -125 |
| Investing Cash Flow | $-196 | $-143 |
| Cash Flows From Financing Activities | ||
| Debt Issued | 1,573 | 610 |
| Other Financing Activity | 5,187 | 3,063 |
| Financing Cash Flow | $6,760 | $3,673 |
| Beginning Cash Position | 707 | 2,413 |
| End Cash Position | 1,074 | 742 |
| Net Cash Flow | $367 | $-1,670 |
| Free Cash Flow | ||
| Operating Cash Flow | -6,197 | -5,200 |
| Capital Expenditure | -196 | -143 |
| Free Cash Flow | -6,393 | -5,343 |